| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonadotropin-Releasing Hormone | 145 | 2022 | 1148 | 9.280 |
Why?
|
| Hypogonadism | 87 | 2023 | 798 | 6.150 |
Why?
|
| Kallmann Syndrome | 31 | 2022 | 139 | 4.460 |
Why?
|
| Luteinizing Hormone | 99 | 2020 | 820 | 3.460 |
Why?
|
| Follicle Stimulating Hormone | 78 | 2020 | 726 | 2.940 |
Why?
|
| Reproduction | 16 | 2016 | 645 | 2.520 |
Why?
|
| Hypothalamus | 27 | 2017 | 999 | 2.140 |
Why?
|
| Gonadotropins | 29 | 2010 | 241 | 1.820 |
Why?
|
| Inhibins | 28 | 2013 | 210 | 1.740 |
Why?
|
| Gastrointestinal Hormones | 8 | 2014 | 101 | 1.680 |
Why?
|
| Receptors, Peptide | 9 | 2018 | 279 | 1.400 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 12 | 2017 | 257 | 1.340 |
Why?
|
| Receptors, LHRH | 20 | 2015 | 158 | 1.310 |
Why?
|
| Pituitary Gland | 28 | 2013 | 635 | 1.240 |
Why?
|
| Receptors, G-Protein-Coupled | 17 | 2018 | 1250 | 1.230 |
Why?
|
| Neuropeptides | 8 | 2014 | 944 | 1.160 |
Why?
|
| Puberty | 15 | 2020 | 501 | 1.150 |
Why?
|
| DNA Helicases | 4 | 2017 | 851 | 1.070 |
Why?
|
| Polycystic Ovary Syndrome | 12 | 2012 | 376 | 0.960 |
Why?
|
| Sexual Maturation | 10 | 2020 | 261 | 0.910 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 15 | 1990 | 36 | 0.890 |
Why?
|
| Puberty, Precocious | 16 | 2008 | 164 | 0.870 |
Why?
|
| Extracellular Matrix Proteins | 12 | 2013 | 829 | 0.840 |
Why?
|
| Endocrine System Diseases | 2 | 2017 | 249 | 0.820 |
Why?
|
| Phenotype | 33 | 2023 | 16571 | 0.820 |
Why?
|
| Pedigree | 33 | 2020 | 4539 | 0.790 |
Why?
|
| Testis | 19 | 2013 | 792 | 0.790 |
Why?
|
| Mutation | 45 | 2023 | 30016 | 0.770 |
Why?
|
| Testosterone | 41 | 2020 | 2472 | 0.730 |
Why?
|
| Hypothalamic Diseases | 4 | 2020 | 134 | 0.730 |
Why?
|
| Olfaction Disorders | 8 | 2020 | 224 | 0.690 |
Why?
|
| Neurosecretory Systems | 10 | 2019 | 223 | 0.680 |
Why?
|
| Academic Medical Centers | 9 | 2013 | 2756 | 0.600 |
Why?
|
| Estradiol | 27 | 2008 | 1937 | 0.600 |
Why?
|
| Gonadal Steroid Hormones | 13 | 2020 | 702 | 0.600 |
Why?
|
| DNA-Binding Proteins | 11 | 2017 | 9586 | 0.600 |
Why?
|
| Dwarfism, Pituitary | 1 | 2018 | 39 | 0.580 |
Why?
|
| Neurokinin B | 2 | 2015 | 67 | 0.570 |
Why?
|
| Genitalia | 1 | 2017 | 113 | 0.560 |
Why?
|
| Gonadotropins, Pituitary | 10 | 2001 | 69 | 0.560 |
Why?
|
| Gonadotrophs | 1 | 2017 | 19 | 0.560 |
Why?
|
| Amenorrhea | 13 | 2012 | 483 | 0.520 |
Why?
|
| Fibroblast Growth Factor 8 | 3 | 2013 | 62 | 0.520 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2009 | 794 | 0.510 |
Why?
|
| Mutation, Missense | 7 | 2019 | 2570 | 0.510 |
Why?
|
| Periodicity | 16 | 2011 | 347 | 0.510 |
Why?
|
| Research Support as Topic | 6 | 2004 | 697 | 0.500 |
Why?
|
| Repressor Proteins | 8 | 2022 | 2985 | 0.470 |
Why?
|
| Awards and Prizes | 4 | 2014 | 360 | 0.470 |
Why?
|
| Deficiency Diseases | 1 | 2014 | 74 | 0.470 |
Why?
|
| Research | 6 | 2007 | 1977 | 0.460 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1392 | 0.460 |
Why?
|
| Menstrual Cycle | 15 | 2007 | 539 | 0.440 |
Why?
|
| Endocrinology | 5 | 2014 | 442 | 0.440 |
Why?
|
| Glycoproteins | 11 | 2002 | 2200 | 0.440 |
Why?
|
| Chronobiology Disorders | 1 | 2014 | 73 | 0.420 |
Why?
|
| Hypothalamo-Hypophyseal System | 9 | 2011 | 701 | 0.420 |
Why?
|
| Puberty, Delayed | 7 | 2012 | 121 | 0.420 |
Why?
|
| Nerve Tissue Proteins | 13 | 2013 | 4408 | 0.410 |
Why?
|
| Receptors, Retinoic Acid | 7 | 2002 | 224 | 0.400 |
Why?
|
| Fertility | 6 | 2010 | 769 | 0.400 |
Why?
|
| Neurons | 12 | 2020 | 9438 | 0.400 |
Why?
|
| Gonads | 7 | 2020 | 109 | 0.400 |
Why?
|
| Biomedical Research | 8 | 2013 | 3426 | 0.390 |
Why?
|
| Ovary | 14 | 2011 | 959 | 0.370 |
Why?
|
| Follicular Phase | 11 | 1997 | 143 | 0.370 |
Why?
|
| Seminiferous Tubules | 2 | 2009 | 25 | 0.360 |
Why?
|
| Infertility | 3 | 2010 | 654 | 0.350 |
Why?
|
| Humans | 244 | 2023 | 760617 | 0.340 |
Why?
|
| Radioimmunoassay | 15 | 1995 | 861 | 0.340 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 8 | 2009 | 29 | 0.340 |
Why?
|
| Ovulation Induction | 8 | 2000 | 277 | 0.330 |
Why?
|
| Zebrafish | 3 | 2022 | 3007 | 0.330 |
Why?
|
| Immunoassay | 3 | 2007 | 744 | 0.320 |
Why?
|
| Luteal Phase | 10 | 1998 | 138 | 0.300 |
Why?
|
| Genomics | 3 | 2016 | 5822 | 0.300 |
Why?
|
| Models, Organizational | 2 | 2009 | 544 | 0.300 |
Why?
|
| Male | 150 | 2020 | 360358 | 0.300 |
Why?
|
| Genetic Association Studies | 6 | 2020 | 2734 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2020 | 2801 | 0.290 |
Why?
|
| Bone Development | 7 | 1991 | 470 | 0.290 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 353 | 0.280 |
Why?
|
| Adult | 116 | 2023 | 220969 | 0.280 |
Why?
|
| Androgens | 11 | 2006 | 1285 | 0.270 |
Why?
|
| CHARGE Syndrome | 2 | 2017 | 33 | 0.270 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 7 | 2000 | 95 | 0.270 |
Why?
|
| Population | 1 | 2006 | 141 | 0.260 |
Why?
|
| Signal Transduction | 7 | 2020 | 23416 | 0.260 |
Why?
|
| X Chromosome | 7 | 2001 | 816 | 0.260 |
Why?
|
| Female | 150 | 2023 | 392148 | 0.260 |
Why?
|
| Progesterone | 15 | 1998 | 742 | 0.260 |
Why?
|
| Genetic Markers | 2 | 2010 | 2601 | 0.250 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2011 | 191 | 0.250 |
Why?
|
| Aromatase Inhibitors | 5 | 2007 | 513 | 0.250 |
Why?
|
| Metabolism | 1 | 2006 | 193 | 0.250 |
Why?
|
| Animals | 58 | 2023 | 168201 | 0.240 |
Why?
|
| Nose | 2 | 2020 | 521 | 0.240 |
Why?
|
| Infertility, Male | 3 | 2013 | 396 | 0.230 |
Why?
|
| Fibroblast Growth Factors | 3 | 2017 | 865 | 0.230 |
Why?
|
| Genetic Variation | 5 | 2016 | 6561 | 0.220 |
Why?
|
| Pituitary Gland, Anterior | 5 | 1996 | 142 | 0.220 |
Why?
|
| Government Agencies | 1 | 2004 | 160 | 0.220 |
Why?
|
| Polymorphism, Genetic | 4 | 2013 | 4242 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1626 | 0.210 |
Why?
|
| Receptors, FSH | 5 | 1998 | 29 | 0.210 |
Why?
|
| Ovarian Follicle | 4 | 1999 | 244 | 0.200 |
Why?
|
| Adolescent | 57 | 2020 | 88234 | 0.200 |
Why?
|
| Chorionic Gonadotropin | 4 | 2001 | 457 | 0.200 |
Why?
|
| Libido | 2 | 2020 | 124 | 0.200 |
Why?
|
| Protein Precursors | 5 | 2011 | 1131 | 0.190 |
Why?
|
| Feedback | 11 | 2001 | 790 | 0.190 |
Why?
|
| Private Sector | 2 | 2004 | 394 | 0.190 |
Why?
|
| Spermatogenesis | 5 | 2010 | 258 | 0.190 |
Why?
|
| Adrenal Insufficiency | 2 | 2001 | 194 | 0.190 |
Why?
|
| Base Sequence | 15 | 2014 | 12421 | 0.190 |
Why?
|
| Amino Acid Substitution | 5 | 2020 | 1739 | 0.180 |
Why?
|
| SOXE Transcription Factors | 1 | 2021 | 73 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2017 | 3805 | 0.180 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2020 | 29 | 0.180 |
Why?
|
| Developmental Biology | 2 | 2011 | 79 | 0.180 |
Why?
|
| Molecular Sequence Data | 15 | 2014 | 17629 | 0.180 |
Why?
|
| Receptors, Neurokinin-3 | 2 | 2010 | 59 | 0.170 |
Why?
|
| Body Height | 8 | 2001 | 1565 | 0.170 |
Why?
|
| Spatial Behavior | 1 | 2020 | 88 | 0.170 |
Why?
|
| Drug Approval | 1 | 2007 | 812 | 0.170 |
Why?
|
| Genetic Linkage | 8 | 2003 | 2340 | 0.170 |
Why?
|
| Follicular Fluid | 4 | 1996 | 92 | 0.170 |
Why?
|
| Genotype | 10 | 2021 | 12978 | 0.170 |
Why?
|
| Gene Deletion | 4 | 2015 | 2661 | 0.170 |
Why?
|
| Genetic Techniques | 1 | 2002 | 428 | 0.160 |
Why?
|
| Transcription Factors | 11 | 2019 | 12116 | 0.160 |
Why?
|
| Activins | 11 | 1998 | 210 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2020 | 310 | 0.160 |
Why?
|
| Steroids | 2 | 2020 | 929 | 0.160 |
Why?
|
| Adrenal Glands | 5 | 2001 | 552 | 0.160 |
Why?
|
| Cooperative Behavior | 4 | 2013 | 1504 | 0.160 |
Why?
|
| Heterozygote | 7 | 2023 | 2780 | 0.160 |
Why?
|
| Abnormalities, Multiple | 3 | 2020 | 1422 | 0.160 |
Why?
|
| Corpus Luteum | 3 | 1996 | 81 | 0.160 |
Why?
|
| Medical Informatics | 1 | 2005 | 732 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2020 | 430 | 0.150 |
Why?
|
| Estrogens | 5 | 2000 | 1521 | 0.150 |
Why?
|
| Body Weight | 4 | 2006 | 4614 | 0.150 |
Why?
|
| DNA Mutational Analysis | 9 | 2020 | 4110 | 0.150 |
Why?
|
| Recombinant Proteins | 13 | 2013 | 6520 | 0.150 |
Why?
|
| Reference Values | 13 | 1998 | 4919 | 0.150 |
Why?
|
| Endocrine System | 1 | 1998 | 114 | 0.150 |
Why?
|
| Research Personnel | 3 | 2004 | 588 | 0.150 |
Why?
|
| Neural Crest | 1 | 2020 | 279 | 0.150 |
Why?
|
| Ovulation | 9 | 2004 | 181 | 0.150 |
Why?
|
| Hospitals, General | 2 | 2001 | 798 | 0.140 |
Why?
|
| Mice, Knockout | 6 | 2017 | 14389 | 0.140 |
Why?
|
| Computational Biology | 2 | 2013 | 3509 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 1998 | 277 | 0.140 |
Why?
|
| Choanal Atresia | 1 | 2017 | 41 | 0.140 |
Why?
|
| Microphthalmos | 1 | 2017 | 58 | 0.140 |
Why?
|
| Pregnancy, Multiple | 2 | 1994 | 215 | 0.130 |
Why?
|
| Menstruation | 7 | 2011 | 306 | 0.130 |
Why?
|
| Growth Substances | 1 | 1998 | 768 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2007 | 7995 | 0.130 |
Why?
|
| Follistatin | 9 | 1998 | 137 | 0.130 |
Why?
|
| Growth | 2 | 1991 | 365 | 0.130 |
Why?
|
| Receptors, Neuropeptide | 3 | 2005 | 106 | 0.120 |
Why?
|
| Genetic Testing | 4 | 2013 | 3533 | 0.120 |
Why?
|
| Haplotypes | 5 | 2015 | 2713 | 0.120 |
Why?
|
| Otolithic Membrane | 1 | 2014 | 38 | 0.120 |
Why?
|
| Codon, Nonsense | 2 | 2014 | 284 | 0.120 |
Why?
|
| Clinical Medicine | 2 | 2009 | 145 | 0.120 |
Why?
|
| Mice | 13 | 2023 | 81368 | 0.120 |
Why?
|
| Reproductive Techniques | 1 | 1994 | 41 | 0.120 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 390 | 0.120 |
Why?
|
| Leuprolide | 1 | 2016 | 312 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 1133 | 0.120 |
Why?
|
| Sperm Count | 4 | 2013 | 229 | 0.120 |
Why?
|
| Amino Acid Sequence | 9 | 2011 | 13441 | 0.110 |
Why?
|
| Cataract | 1 | 2020 | 831 | 0.110 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 1015 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 3 | 2013 | 750 | 0.110 |
Why?
|
| Endocrine Glands | 3 | 2002 | 101 | 0.110 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.110 |
Why?
|
| Voluntary Programs | 1 | 2013 | 48 | 0.110 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2013 | 13 | 0.110 |
Why?
|
| Genes, Recessive | 4 | 2003 | 623 | 0.110 |
Why?
|
| Time Factors | 20 | 2020 | 39913 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 3705 | 0.110 |
Why?
|
| Synkinesis | 1 | 2013 | 23 | 0.110 |
Why?
|
| Anodontia | 1 | 2013 | 50 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2010 | 10754 | 0.110 |
Why?
|
| Mobius Syndrome | 1 | 2013 | 41 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1994 | 239 | 0.110 |
Why?
|
| Finger Phalanges | 1 | 2013 | 41 | 0.100 |
Why?
|
| Genetic Load | 1 | 2012 | 15 | 0.100 |
Why?
|
| Pituitary Hormones, Anterior | 3 | 1989 | 56 | 0.100 |
Why?
|
| Ovarian Diseases | 2 | 1991 | 136 | 0.100 |
Why?
|
| Cohort Studies | 12 | 2020 | 41457 | 0.100 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2012 | 33 | 0.100 |
Why?
|
| Hospital Charges | 1 | 1994 | 350 | 0.100 |
Why?
|
| Organ Size | 3 | 2020 | 2252 | 0.100 |
Why?
|
| Age of Onset | 3 | 2010 | 3302 | 0.100 |
Why?
|
| Syndrome | 3 | 2015 | 3268 | 0.100 |
Why?
|
| Massachusetts | 5 | 2013 | 8833 | 0.100 |
Why?
|
| Nervous System | 1 | 2015 | 545 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 243 | 0.100 |
Why?
|
| Founder Effect | 1 | 2012 | 185 | 0.100 |
Why?
|
| Peptide Fragments | 4 | 2007 | 5110 | 0.100 |
Why?
|
| Infusions, Intravenous | 6 | 2007 | 2214 | 0.100 |
Why?
|
| Drug Administration Schedule | 8 | 2007 | 4845 | 0.100 |
Why?
|
| HEK293 Cells | 2 | 2018 | 4269 | 0.100 |
Why?
|
| Infusion Pumps | 2 | 1989 | 163 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 725 | 0.100 |
Why?
|
| Biological Clocks | 1 | 2014 | 318 | 0.090 |
Why?
|
| Hormones | 5 | 2006 | 869 | 0.090 |
Why?
|
| Disorders of Sex Development | 2 | 2006 | 128 | 0.090 |
Why?
|
| Age Determination by Skeleton | 3 | 1988 | 126 | 0.090 |
Why?
|
| Patient Advocacy | 1 | 2013 | 360 | 0.090 |
Why?
|
| Infertility, Female | 3 | 1999 | 760 | 0.090 |
Why?
|
| Pituitary-Adrenal System | 2 | 2004 | 552 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1894 | 0.090 |
Why?
|
| Estrone | 3 | 2007 | 234 | 0.090 |
Why?
|
| Dehydroepiandrosterone Sulfate | 6 | 2004 | 241 | 0.090 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 2 | 2008 | 94 | 0.090 |
Why?
|
| Sulfotransferases | 1 | 2011 | 150 | 0.090 |
Why?
|
| Alleles | 3 | 2020 | 6861 | 0.090 |
Why?
|
| Receptors, Tachykinin | 1 | 2010 | 25 | 0.090 |
Why?
|
| Testolactone | 2 | 1991 | 5 | 0.090 |
Why?
|
| Data Collection | 3 | 2013 | 3315 | 0.090 |
Why?
|
| Olfactory Bulb | 1 | 2011 | 197 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1608 | 0.090 |
Why?
|
| Pulsatile Flow | 4 | 2000 | 321 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1996 | 1208 | 0.090 |
Why?
|
| Tachykinins | 1 | 2010 | 77 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 4739 | 0.080 |
Why?
|
| Siblings | 1 | 2014 | 824 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 17878 | 0.080 |
Why?
|
| Cell Movement | 3 | 2011 | 5200 | 0.080 |
Why?
|
| Middle Aged | 33 | 2020 | 220584 | 0.080 |
Why?
|
| Child | 27 | 2020 | 80079 | 0.080 |
Why?
|
| Vomiting | 1 | 2013 | 651 | 0.080 |
Why?
|
| Chromatography, Gel | 3 | 1996 | 645 | 0.080 |
Why?
|
| Kinetics | 9 | 1994 | 6370 | 0.080 |
Why?
|
| Growth Hormone | 3 | 1989 | 569 | 0.080 |
Why?
|
| Tubulin | 1 | 2013 | 692 | 0.080 |
Why?
|
| United States | 13 | 2013 | 72272 | 0.080 |
Why?
|
| Blood Proteins | 1 | 1994 | 1172 | 0.080 |
Why?
|
| Cryptorchidism | 2 | 2002 | 151 | 0.080 |
Why?
|
| Genetic Heterogeneity | 3 | 2008 | 733 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2011 | 5433 | 0.080 |
Why?
|
| Embalming | 1 | 1988 | 13 | 0.080 |
Why?
|
| Osteoporosis | 2 | 1989 | 1604 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2017 | 7847 | 0.080 |
Why?
|
| Seminiferous Epithelium | 1 | 2008 | 9 | 0.080 |
Why?
|
| Information Systems | 2 | 2008 | 396 | 0.080 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 12661 | 0.080 |
Why?
|
| Physicians | 1 | 2006 | 4583 | 0.080 |
Why?
|
| Ketoconazole | 3 | 2007 | 97 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 1850 | 0.080 |
Why?
|
| Estriol | 1 | 2007 | 53 | 0.080 |
Why?
|
| Ligands | 4 | 2010 | 3268 | 0.080 |
Why?
|
| Dehydroepiandrosterone | 5 | 1988 | 258 | 0.080 |
Why?
|
| Blood Specimen Collection | 2 | 1994 | 238 | 0.070 |
Why?
|
| Industry | 2 | 2003 | 364 | 0.070 |
Why?
|
| Societies, Scientific | 1 | 2009 | 222 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2008 | 137 | 0.070 |
Why?
|
| DNA | 8 | 2012 | 7196 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3792 | 0.070 |
Why?
|
| Gynecomastia | 1 | 1988 | 86 | 0.070 |
Why?
|
| Systems Biology | 1 | 2011 | 481 | 0.070 |
Why?
|
| Ovarian Neoplasms | 6 | 1998 | 4849 | 0.070 |
Why?
|
| Somatomedins | 1 | 1988 | 179 | 0.070 |
Why?
|
| Pulse Therapy, Drug | 2 | 2013 | 37 | 0.070 |
Why?
|
| Estrenes | 1 | 1986 | 21 | 0.070 |
Why?
|
| Societies, Medical | 4 | 2014 | 3900 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2011 | 627 | 0.070 |
Why?
|
| Abortifacient Agents | 1 | 1986 | 11 | 0.070 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 1986 | 22 | 0.070 |
Why?
|
| Secretory Rate | 3 | 1996 | 81 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2011 | 2747 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2011 | 721 | 0.070 |
Why?
|
| COS Cells | 4 | 2017 | 1130 | 0.070 |
Why?
|
| RNA, Messenger | 9 | 2005 | 12758 | 0.070 |
Why?
|
| Adolescent Development | 2 | 2020 | 281 | 0.070 |
Why?
|
| Research Subjects | 1 | 2008 | 249 | 0.070 |
Why?
|
| Rats, Inbred Strains | 5 | 1992 | 2088 | 0.070 |
Why?
|
| Receptors, Galanin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Pregnancy | 14 | 2006 | 29868 | 0.070 |
Why?
|
| Iceland | 1 | 2006 | 184 | 0.070 |
Why?
|
| Case-Control Studies | 6 | 2014 | 22148 | 0.070 |
Why?
|
| Rats | 14 | 1996 | 23717 | 0.070 |
Why?
|
| Epitopes | 3 | 1994 | 2501 | 0.070 |
Why?
|
| Models, Animal | 2 | 2010 | 2109 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 5 | 1996 | 9172 | 0.070 |
Why?
|
| Child, Preschool | 17 | 2020 | 42188 | 0.070 |
Why?
|
| Osmolar Concentration | 3 | 1995 | 659 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 10199 | 0.070 |
Why?
|
| Melatonin | 1 | 1991 | 669 | 0.070 |
Why?
|
| Acanthosis Nigricans | 1 | 1985 | 47 | 0.060 |
Why?
|
| Hirsutism | 1 | 1985 | 68 | 0.060 |
Why?
|
| Hearing Loss | 1 | 2013 | 781 | 0.060 |
Why?
|
| Biological Assay | 5 | 2006 | 626 | 0.060 |
Why?
|
| Olfactory Pathways | 2 | 2020 | 132 | 0.060 |
Why?
|
| Adrenal Cortex | 1 | 1986 | 134 | 0.060 |
Why?
|
| Nitriles | 2 | 2001 | 971 | 0.060 |
Why?
|
| Homozygote | 4 | 2010 | 1776 | 0.060 |
Why?
|
| Triazoles | 2 | 2001 | 903 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 518 | 0.060 |
Why?
|
| Thecoma | 1 | 1984 | 11 | 0.060 |
Why?
|
| Factor VII | 1 | 2005 | 139 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 2222 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2008 | 3601 | 0.060 |
Why?
|
| Macaca mulatta | 3 | 2007 | 2328 | 0.060 |
Why?
|
| Proteins | 3 | 2020 | 6030 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2022 | 569 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 369 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 933 | 0.060 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2004 | 33 | 0.060 |
Why?
|
| Gene Expression Regulation | 5 | 2007 | 11874 | 0.060 |
Why?
|
| Safety | 1 | 2008 | 1149 | 0.060 |
Why?
|
| Survivors | 1 | 1994 | 2372 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2008 | 604 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 29600 | 0.060 |
Why?
|
| Cross Reactions | 5 | 1996 | 816 | 0.060 |
Why?
|
| Science | 1 | 2006 | 239 | 0.060 |
Why?
|
| International Cooperation | 1 | 2010 | 1421 | 0.060 |
Why?
|
| Young Adult | 11 | 2020 | 59179 | 0.060 |
Why?
|
| Menorrhagia | 1 | 1983 | 59 | 0.050 |
Why?
|
| Neurogenesis | 2 | 2020 | 862 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2007 | 1162 | 0.050 |
Why?
|
| Societies | 1 | 2004 | 107 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2011 | 1380 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2872 | 0.050 |
Why?
|
| Injections, Intravenous | 4 | 1990 | 1376 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1988 | 1932 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 1985 | 412 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2004 | 236 | 0.050 |
Why?
|
| Career Choice | 1 | 2009 | 756 | 0.050 |
Why?
|
| Antibody Specificity | 4 | 1996 | 1058 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1490 | 0.050 |
Why?
|
| Injections, Subcutaneous | 5 | 1992 | 671 | 0.050 |
Why?
|
| Perfusion | 4 | 1995 | 1373 | 0.050 |
Why?
|
| Molecular Weight | 4 | 1996 | 2185 | 0.050 |
Why?
|
| Cognition | 1 | 2020 | 6987 | 0.050 |
Why?
|
| Hemostatics | 1 | 2005 | 240 | 0.050 |
Why?
|
| Community Networks | 1 | 2004 | 201 | 0.050 |
Why?
|
| Contraceptive Agents, Male | 1 | 1981 | 8 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 350 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18221 | 0.050 |
Why?
|
| Sensitivity and Specificity | 7 | 2007 | 14648 | 0.050 |
Why?
|
| Diagnosis, Differential | 5 | 1998 | 12966 | 0.050 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2002 | 107 | 0.050 |
Why?
|
| Eunuchism | 1 | 2001 | 19 | 0.050 |
Why?
|
| Testicular Hormones | 1 | 2002 | 188 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4512 | 0.050 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2023 | 286 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2005 | 414 | 0.050 |
Why?
|
| Boston | 2 | 2006 | 9313 | 0.050 |
Why?
|
| Infant | 8 | 2020 | 36152 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2010 | 3431 | 0.050 |
Why?
|
| Insulin | 4 | 2006 | 6593 | 0.040 |
Why?
|
| Cerebellar Ataxia | 1 | 2002 | 150 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 375 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 150 | 0.040 |
Why?
|
| Cleft Palate | 1 | 2006 | 589 | 0.040 |
Why?
|
| Symporters | 1 | 2003 | 363 | 0.040 |
Why?
|
| Physical Examination | 1 | 2006 | 1254 | 0.040 |
Why?
|
| Organizational Case Studies | 1 | 2001 | 301 | 0.040 |
Why?
|
| Proprotein Convertases | 1 | 2000 | 95 | 0.040 |
Why?
|
| Total Quality Management | 1 | 2001 | 262 | 0.040 |
Why?
|
| Family Health | 1 | 2004 | 1253 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2006 | 12943 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1490 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2013 | 3238 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 15908 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2014 | 18937 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2022 | 471 | 0.040 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2002 | 407 | 0.040 |
Why?
|
| CHO Cells | 3 | 2010 | 1387 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2001 | 426 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 622 | 0.040 |
Why?
|
| Bone and Bones | 1 | 1989 | 2565 | 0.040 |
Why?
|
| Space Perception | 1 | 1982 | 465 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2000 | 311 | 0.040 |
Why?
|
| History, 20th Century | 2 | 1997 | 2764 | 0.040 |
Why?
|
| Leiomyoma | 1 | 1983 | 636 | 0.040 |
Why?
|
| Health Services | 1 | 2004 | 751 | 0.040 |
Why?
|
| Hospital Information Systems | 1 | 2001 | 394 | 0.040 |
Why?
|
| Epidemiology | 1 | 2001 | 279 | 0.040 |
Why?
|
| Dipeptides | 1 | 2000 | 391 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2020 | 336 | 0.040 |
Why?
|
| Receptors, Growth Factor | 2 | 1996 | 326 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2006 | 3965 | 0.040 |
Why?
|
| Cricetinae | 3 | 2010 | 2424 | 0.040 |
Why?
|
| Blotting, Western | 5 | 1996 | 5034 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 1994 | 1141 | 0.040 |
Why?
|
| Age Factors | 4 | 2020 | 18381 | 0.040 |
Why?
|
| Brain | 3 | 2020 | 27101 | 0.040 |
Why?
|
| Sleep | 1 | 2014 | 4758 | 0.040 |
Why?
|
| Reproductive Medicine | 1 | 1999 | 99 | 0.040 |
Why?
|
| Granulosa Cell Tumor | 1 | 1998 | 77 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2020 | 851 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 1079 | 0.040 |
Why?
|
| Inositol Phosphates | 2 | 2010 | 176 | 0.040 |
Why?
|
| Cricetulus | 2 | 2010 | 814 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2001 | 1947 | 0.040 |
Why?
|
| Menopause | 3 | 1992 | 1645 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15828 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 306 | 0.030 |
Why?
|
| Teratocarcinoma | 1 | 1996 | 16 | 0.030 |
Why?
|
| Vinyl Compounds | 1 | 2016 | 22 | 0.030 |
Why?
|
| Foundations | 1 | 1996 | 95 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2004 | 1403 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1996 | 116 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 1977 | 318 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 149 | 0.030 |
Why?
|
| Estrus | 2 | 1987 | 70 | 0.030 |
Why?
|
| Nerve Net | 1 | 2008 | 2290 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2010 | 39063 | 0.030 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 1452 | 0.030 |
Why?
|
| Hypothyroidism | 2 | 1978 | 667 | 0.030 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 1997 | 118 | 0.030 |
Why?
|
| Feedback, Physiological | 2 | 2008 | 475 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2004 | 2160 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1996 | 813 | 0.030 |
Why?
|
| Epithelium | 2 | 2016 | 1603 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 4611 | 0.030 |
Why?
|
| Program Development | 1 | 2001 | 1293 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 1996 | 258 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 1983 | 1420 | 0.030 |
Why?
|
| Triplets | 1 | 1994 | 42 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1031 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 1748 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1994 | 1738 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1977 | 831 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 1972 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 262 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 9026 | 0.030 |
Why?
|
| Remission, Spontaneous | 2 | 2007 | 384 | 0.030 |
Why?
|
| Fertilization in Vitro | 2 | 1999 | 1292 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2001 | 618 | 0.030 |
Why?
|
| Smell | 2 | 2009 | 259 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 2020 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 1997 | 444 | 0.030 |
Why?
|
| Binding Sites | 3 | 2004 | 6051 | 0.030 |
Why?
|
| Disease Progression | 1 | 2010 | 13495 | 0.030 |
Why?
|
| Thyroxine | 1 | 1977 | 665 | 0.030 |
Why?
|
| Androstenedione | 2 | 2001 | 131 | 0.030 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1993 | 47 | 0.030 |
Why?
|
| Sequence Homology | 1 | 2013 | 196 | 0.030 |
Why?
|
| Lod Score | 2 | 2003 | 600 | 0.030 |
Why?
|
| Twins | 1 | 1994 | 340 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2001 | 1204 | 0.030 |
Why?
|
| Thyrotropin | 3 | 1996 | 834 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2013 | 64568 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2001 | 2486 | 0.030 |
Why?
|
| Luciferases | 1 | 1994 | 712 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2013 | 269 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 1995 | 273 | 0.020 |
Why?
|
| Macromolecular Substances | 3 | 1996 | 1433 | 0.020 |
Why?
|
| Aged | 8 | 2020 | 169042 | 0.020 |
Why?
|
| Uterus | 3 | 1987 | 649 | 0.020 |
Why?
|
| Antibodies | 2 | 1990 | 2414 | 0.020 |
Why?
|
| Poly A | 1 | 1992 | 181 | 0.020 |
Why?
|
| Priapism | 1 | 1991 | 28 | 0.020 |
Why?
|
| Fetus | 1 | 1998 | 1862 | 0.020 |
Why?
|
| Transfection | 2 | 2010 | 5766 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 1996 | 937 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2020 | 26180 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 341 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3680 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 1991 | 366 | 0.020 |
Why?
|
| Genes, Helminth | 1 | 2011 | 146 | 0.020 |
Why?
|
| Mass Screening | 1 | 2006 | 5424 | 0.020 |
Why?
|
| Health Policy | 1 | 2003 | 2682 | 0.020 |
Why?
|
| Vagina | 1 | 2016 | 841 | 0.020 |
Why?
|
| Disease Management | 1 | 2001 | 2506 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2079 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 22115 | 0.020 |
Why?
|
| Body Composition | 1 | 1999 | 2426 | 0.020 |
Why?
|
| Azoospermia | 1 | 2010 | 28 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2187 | 0.020 |
Why?
|
| Glycopeptides | 1 | 1991 | 220 | 0.020 |
Why?
|
| Health Personnel | 1 | 2004 | 3333 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1996 | 2358 | 0.020 |
Why?
|
| Gene Expression | 4 | 2011 | 7568 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4570 | 0.020 |
Why?
|
| Schools, Medical | 1 | 1996 | 878 | 0.020 |
Why?
|
| DNA Primers | 2 | 2009 | 2817 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 2 | 2004 | 58 | 0.020 |
Why?
|
| Body Fluids | 1 | 1991 | 320 | 0.020 |
Why?
|
| Aging | 3 | 1998 | 8699 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 895 | 0.020 |
Why?
|
| Weight Gain | 1 | 1999 | 2350 | 0.020 |
Why?
|
| Pituitary Neoplasms | 2 | 1989 | 1323 | 0.020 |
Why?
|
| Cell Division | 4 | 1997 | 4457 | 0.020 |
Why?
|
| Leydig Cells | 1 | 1988 | 55 | 0.020 |
Why?
|
| Aequorin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Ultrasonography | 3 | 2011 | 5964 | 0.020 |
Why?
|
| Calcifediol | 1 | 1989 | 161 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 58894 | 0.020 |
Why?
|
| Chronobiology Phenomena | 1 | 1988 | 29 | 0.020 |
Why?
|
| Circadian Rhythm | 2 | 1991 | 2569 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2014 | 1565 | 0.020 |
Why?
|
| Calcitriol | 1 | 1989 | 296 | 0.020 |
Why?
|
| Injections | 1 | 1991 | 832 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 1989 | 182 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2008 | 144 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 614 | 0.020 |
Why?
|
| Sex Characteristics | 2 | 2010 | 2637 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 3879 | 0.020 |
Why?
|
| Adenoma | 2 | 1989 | 2159 | 0.020 |
Why?
|
| Exons | 2 | 1991 | 2381 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 8166 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3800 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 2411 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2008 | 14591 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 426 | 0.020 |
Why?
|
| Forearm | 1 | 1989 | 427 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 509 | 0.020 |
Why?
|
| Activin Receptors | 2 | 1996 | 40 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 860 | 0.020 |
Why?
|
| Hypothalamic Neoplasms | 1 | 1986 | 21 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 1996 | 20074 | 0.020 |
Why?
|
| Carcinoma | 1 | 1997 | 2327 | 0.020 |
Why?
|
| Mifepristone | 1 | 1986 | 151 | 0.020 |
Why?
|
| Ferritins | 1 | 2008 | 597 | 0.020 |
Why?
|
| Swine | 2 | 1995 | 5907 | 0.020 |
Why?
|
| Point Mutation | 2 | 2004 | 1595 | 0.020 |
Why?
|
| Genes | 1 | 1989 | 1823 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2006 | 231 | 0.020 |
Why?
|
| Receptors, LH | 2 | 1997 | 18 | 0.020 |
Why?
|
| Prevalence | 1 | 2022 | 15689 | 0.020 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 1986 | 98 | 0.020 |
Why?
|
| Models, Biological | 3 | 2008 | 9461 | 0.020 |
Why?
|
| Luteinizing Hormone, beta Subunit | 1 | 2004 | 11 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1985 | 361 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2011 | 871 | 0.010 |
Why?
|
| Sex | 1 | 1984 | 53 | 0.010 |
Why?
|
| Immune Sera | 2 | 1995 | 605 | 0.010 |
Why?
|
| Factor VIIa | 1 | 2005 | 103 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 3 | 1996 | 6126 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2004 | 225 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 1650 | 0.010 |
Why?
|
| Radius | 1 | 1987 | 441 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 271 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 1880 | 0.010 |
Why?
|
| Hamartoma | 1 | 1986 | 235 | 0.010 |
Why?
|
| Heart | 1 | 1977 | 4403 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1984 | 2802 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1994 | 2921 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1990 | 1170 | 0.010 |
Why?
|
| United States Government Agencies | 1 | 2003 | 26 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1991 | 4010 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 928 | 0.010 |
Why?
|
| Haplorhini | 1 | 1984 | 525 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 11459 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1989 | 1803 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2006 | 942 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1265 | 0.010 |
Why?
|
| Placenta | 2 | 2006 | 1709 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1983 | 207 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6224 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1985 | 1178 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1992 | 6338 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 3688 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 623 | 0.010 |
Why?
|
| Platelet Count | 1 | 2005 | 780 | 0.010 |
Why?
|
| Progestins | 1 | 1984 | 301 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1987 | 1964 | 0.010 |
Why?
|
| 17-alpha-Hydroxypregnenolone | 1 | 2001 | 5 | 0.010 |
Why?
|
| Protein Binding | 1 | 1994 | 9345 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2001 | 21 | 0.010 |
Why?
|
| Breast | 1 | 2011 | 1963 | 0.010 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2001 | 56 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 15576 | 0.010 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1745 | 0.010 |
Why?
|
| Cyclic AMP | 2 | 1997 | 1463 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 2001 | 106 | 0.010 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2001 | 99 | 0.010 |
Why?
|
| Investments | 1 | 2003 | 147 | 0.010 |
Why?
|
| Health Occupations | 1 | 2003 | 223 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1389 | 0.010 |
Why?
|
| Insulin Resistance | 2 | 2004 | 3954 | 0.010 |
Why?
|
| Menstruation-Inducing Agents | 1 | 1980 | 2 | 0.010 |
Why?
|
| Cervix Mucus | 1 | 1980 | 18 | 0.010 |
Why?
|
| Apoptosis | 1 | 1996 | 9476 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2019 | 80566 | 0.010 |
Why?
|
| Douglas' Pouch | 1 | 1979 | 1 | 0.010 |
Why?
|
| Spine | 1 | 1987 | 1112 | 0.010 |
Why?
|
| Health Priorities | 1 | 2003 | 375 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 2208 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1999 | 163 | 0.010 |
Why?
|
| Institutional Practice | 1 | 1999 | 16 | 0.010 |
Why?
|
| Giant Cell Arteritis | 1 | 2004 | 306 | 0.010 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 11106 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1985 | 2668 | 0.010 |
Why?
|
| Orchiectomy | 1 | 2001 | 463 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 11069 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1983 | 631 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1900 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2005 | 1185 | 0.010 |
Why?
|
| Policy Making | 1 | 2003 | 541 | 0.010 |
Why?
|
| Prednisone | 1 | 2004 | 1562 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2008 | 54360 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 2467 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 1524 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1996 | 4172 | 0.010 |
Why?
|
| Confidentiality | 1 | 2003 | 608 | 0.010 |
Why?
|
| Bacteria | 1 | 1989 | 2192 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2218 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1991 | 4935 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2005 | 1299 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2003 | 553 | 0.010 |
Why?
|
| Obesity | 1 | 1999 | 12933 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1985 | 1779 | 0.010 |
Why?
|
| Internet | 1 | 2009 | 3090 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 1140 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1996 | 20 | 0.010 |
Why?
|
| Postmenopause | 2 | 1996 | 2511 | 0.010 |
Why?
|
| Informed Consent | 1 | 2003 | 1007 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1998 | 340 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1996 | 237 | 0.010 |
Why?
|
| Systole | 1 | 1978 | 935 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1997 | 217 | 0.010 |
Why?
|
| Incidence | 1 | 1994 | 21337 | 0.010 |
Why?
|
| Prolactin | 2 | 1989 | 625 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 1996 | 115 | 0.010 |
Why?
|
| Embryo Transfer | 1 | 1999 | 522 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 416 | 0.010 |
Why?
|
| Kidney | 1 | 1991 | 7045 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 311 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 3680 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 783 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1996 | 522 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 6762 | 0.010 |
Why?
|
| Calibration | 1 | 1996 | 817 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 3608 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1997 | 517 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1978 | 1515 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 1997 | 473 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 3117 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1992 | 184 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 14018 | 0.010 |
Why?
|
| Psychometrics | 1 | 1982 | 3060 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 2491 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1992 | 531 | 0.010 |
Why?
|
| Motivation | 1 | 2001 | 2003 | 0.010 |
Why?
|
| Penile Erection | 1 | 1991 | 101 | 0.010 |
Why?
|
| Cell Separation | 1 | 1996 | 1718 | 0.010 |
Why?
|
| Calcium | 1 | 1984 | 5717 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 4237 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 297 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 26049 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1994 | 1525 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23972 | 0.010 |
Why?
|
| Menarche | 1 | 1992 | 532 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1992 | 613 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1989 | 550 | 0.010 |
Why?
|
| Introns | 1 | 1991 | 968 | 0.000 |
Why?
|
| Blotting, Southern | 1 | 1989 | 777 | 0.000 |
Why?
|
| Restriction Mapping | 1 | 1989 | 851 | 0.000 |
Why?
|
| DNA Probes | 1 | 1989 | 541 | 0.000 |
Why?
|
| Cattle | 1 | 1994 | 3841 | 0.000 |
Why?
|
| Amino Acids | 1 | 1994 | 1717 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1989 | 453 | 0.000 |
Why?
|
| Bromocriptine | 1 | 1987 | 93 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1996 | 5863 | 0.000 |
Why?
|
| Risk Factors | 1 | 1993 | 74115 | 0.000 |
Why?
|
| Ovarian Cysts | 1 | 1986 | 108 | 0.000 |
Why?
|
| Actins | 1 | 1992 | 2050 | 0.000 |
Why?
|
| Homeostasis | 1 | 1996 | 3321 | 0.000 |
Why?
|
| RNA, Neoplasm | 1 | 1987 | 749 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 20556 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1991 | 6074 | 0.000 |
Why?
|
| Dopamine | 1 | 1987 | 1606 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1978 | 288 | 0.000 |
Why?
|
| Thyroid Hormones | 1 | 1978 | 403 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 8516 | 0.000 |
Why?
|